Both PIM and JAK2 inhibitors have been used to downregulate MYC and repress MPN cell proliferation; however, combining them can overcome MPN drug resistance and synergistically enhance their suppressing effect upon MYC [671]. Here, JAK2 is linked to myeloproliferative disorder.